Title: Structure-activity relationship of 2,4,5-trioxoimidazolidines as inhibitors of thymidine phosphorylase.
Journal: European journal of medicinal chemistry 20110401
Title: Structural diversity of nucleoside phosphonic acids as a key factor in the discovery of potent inhibitors of rat T-cell lymphoma thymidine phosphorylase.
Journal: Bioorganic & medicinal chemistry letters 20100201
Title: Schiff bases of 3-formylchromone as thymidine phosphorylase inhibitors.
Journal: Bioorganic & medicinal chemistry 20090415
Title: Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
Journal: European journal of medicinal chemistry 20080601
Title: Induction of thymidine phosphorylase expression by AZT contributes to enhancement of 5'-DFUR cytotoxicity.
Journal: Cancer letters 20061208
Title: Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.
Journal: Journal of medicinal chemistry 20050127
Title: Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.
Journal: Bioorganic & medicinal chemistry letters 20041101
Title: Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase.
Journal: Journal of medicinal chemistry 20030116
Title: Peters GJ, et al. TAS-102: more than an antimetabolite. Lancet Oncol. 2012 Dec;13(12):e518-9.
Title: Yoshino T, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012 Oct;13(10):993-1001.
